129 related articles for article (PubMed ID: 35650451)
1. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
Guo J; Huang L
Nat Protoc; 2022 Aug; 17(8):1818-1831. PubMed ID: 35650451
[TBL] [Abstract][Full Text] [Related]
2. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Guo J; Yu Z; Sun D; Zou Y; Liu Y; Huang L
Mol Cancer; 2021 Jan; 20(1):10. PubMed ID: 33407548
[TBL] [Abstract][Full Text] [Related]
3. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
Guo J; Yu Z; Das M; Huang L
ACS Nano; 2020 Apr; 14(4):5075-5089. PubMed ID: 32283007
[TBL] [Abstract][Full Text] [Related]
4. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract][Full Text] [Related]
5. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
7. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
[TBL] [Abstract][Full Text] [Related]
8. Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
Liu J; Kolath J; Anderson J; Kolar C; Lawson TA; Talmadge J; Gmeiner WH
Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):481-6. PubMed ID: 10555156
[TBL] [Abstract][Full Text] [Related]
9. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
Liu J; Kolar C; Lawson TA; Gmeiner WH
J Org Chem; 2001 Aug; 66(17):5655-63. PubMed ID: 11511236
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
Liu C; Willingham M; Liu J; Gmeiner WH
Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
12. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
13. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
de Gramont A; Tournigand C; Louvet C; André T; Molitor JL; Raymond E; Moreau S; Vignoud J; Le Bail N; Krulik M
Rev Med Interne; 1997; 18(10):769-75. PubMed ID: 9500010
[TBL] [Abstract][Full Text] [Related]
14. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
Machover D; Grison X; Goldschmidt E; Zittoun J; Metzger G; Richaud J; Lotz JP; André T; Hannoun L; Marquet J
Ann Oncol; 1993; 4 Suppl 2():29-35. PubMed ID: 8353102
[TBL] [Abstract][Full Text] [Related]
16. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
17. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
Pardee TS; Gomes E; Jennings-Gee J; Caudell D; Gmeiner WH
Blood; 2012 Apr; 119(15):3561-70. PubMed ID: 22362039
[TBL] [Abstract][Full Text] [Related]
18. Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma.
Chen Y; Li N; Xu B; Wu M; Yan X; Zhong L; Cai H; Wang T; Wang Q; Long F; Jiang G; Xiao H
Biomed Pharmacother; 2019 Oct; 118():109257. PubMed ID: 31377472
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
20. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer.
Abd-Rabou AA; Bharali DJ; Mousa SA
Pharm Res; 2018 Feb; 35(4):76. PubMed ID: 29488022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
